Improving the outcomes that matter most — for your patients and your practice.
This retrospective study examines cancer control and health-related quality of life (HRQOL) outcomes in high-risk prostate cancer patients receiving robotic stereotactic body radiation therapy (SBRT) with Synchrony® real-time adaptive motion management.
This case report explores the dosimetric impact of unmanaged intrafraction prostate motion during radiotherapy by retrospectively analyzing real-time motion data collected using the Radixact® System with Synchrony®. The study models what would have happened if a patient had been treated without motion management, using deformation vector fields to simulate dose
Traditional internal target volume (ITV) methods for the treatment of a lung tumor on conventional linac would require a large planning target volume (PTV), risking high radiation exposure to the chest wall and lungs.
Goddard LC, Cabrera J, Tang J, Garg MK, Tomé WA (Montefiore Medical Center / Albert Einstein College of Medicine, NY, USA).
To evaluate the safety of patients with localized prostate cancer undergoing SBRT using the Radixact® System with Synchrony® Fiducial Tracking™, a real-time motion tracking and correction system.
Not all primary renal cell carcinoma (RCC) patients are suitable for surgery due to the typically late onset of the disease, which is often associated with comorbidities and an increased perioperative risk.
Systemic therapies, particularly targeted agents and immune checkpoint inhibitors (ICIs), have long been the primary treatment approach for metastatic renal cell carcinoma (mRCC). However, when immune-related toxicities arise, alternative approaches to treatment are required.
This case series reports the clinical experience of delivering stereotactic body radiation therapy (SBRT) for localized prostate cancer using the Radixact® X9 System with Synchrony® fiducial-based real-time motion tracking.
This case series investigates the early real-world performance of Synchrony® real-time motion tracking during ultra-hypofractionated prostate radiotherapy on the Radixact® System.
View the clinical evidence and see how health professionals are helping to improve patient outcomes with Accuray technologies.
